• Neos Therapeutics to Host Second Quarter 2019 Financial and Operating Results Conference Call on August 8th, 2019

    Source: Nasdaq GlobeNewswire / 01 Aug 2019 08:02:40   America/New_York

    DALLAS and FORT WORTH, Texas, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report its second quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, August 8, 2019. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.

    The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 8680814. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/ and will be available for replay following the call for 30 days.

    About Neos Therapeutics
    Neos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are three approved products using the Company’s extended-release  technology platform. Additional information about Neos is available at www.neostx.com.

    CONTACTS:

    Richard I. Eisenstadt
    Chief Financial Officer
    Neos Therapeutics
    (972) 408-1389
    reisenstadt@neostx.com

    Sarah McCabe
    Investor Relations
    Stern Investor Relations, Inc.
    (212) 362-1200
    sarah.mccabe@sternir.com

     

    Primary Logo

Share on,